International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 4 July-August 2024 Submit your research before last 3 days of August to publish your research paper in the issue of July-August.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 4
July-August 2024

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

Author(s) Oneesha P.M., Sreejith K., Ashitha Parvin T.K., Ashitha Suresh
Country India
Abstract The only breast cancer (BC) subtype without targeted therapies is triple negative breast cancer (TNBC), which makes for 15–20% of incident breast cancers. TNBC is HER2 (human epidermal growth factor receptor 2) negative using clinical tests, and immunostaining reveals a negligible (1%) expression of ER and PR. It has the most dismal prognosis of all BC subtypes due to its biologically aggressive tumor, which is characterized by moderate/high grade and highly proliferating cancer cells. Although invasive ductal carcinoma is the most frequent presentation of TNBC, there are specific TNBC histologies that require special attention due to differing biology and prognosis. Patients with operable illness are increasingly receiving neoadjuvant chemotherapy, which was formerly reserved for patients with locally progressed or inflamed breast cancer, notably in TNBC patients. More people can have breast-conserving surgery (BCS) thanks to this therapeutic strategy, which also assesses how well it is working. An important prognostic factor with positive long-term results is achieving a pathological complete response (pCR). A higher pCR rate is related to the delivery of NACT regimens with platinum salts. However, at the expense of confusing treatment recommendations there is higher incidence of negative outcomes. Improvements in pathologic complete response rates and patient outcomes in the neoadjuvant setting are the main topics of clinical research.
Keywords Triple negative breast cancer, Neoadjuvant Chemotherapy, pCR
Field Medical / Pharmacy
Published In Volume 5, Issue 2, March-April 2023
Published On 2023-03-23
Cite This Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients - Oneesha P.M., Sreejith K., Ashitha Parvin T.K., Ashitha Suresh - IJFMR Volume 5, Issue 2, March-April 2023. DOI 10.36948/ijfmr.2023.v05i02.1995
DOI https://doi.org/10.36948/ijfmr.2023.v05i02.1995
Short DOI https://doi.org/gr2km2
View / Download PDF File

Share this


E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-5948-55 editor@ijfmr.com